羟基喜树碱肝动脉栓塞治疗原发性肝癌疗效观察  

Effect of Hydroxycamptothecin-based Transcather Arterial Chemoembolization for Primary Liver Cancer

作　　者：燕平[1] 况建荣[1] 熊奎[1] 

机构地区：[1]郧阳医学院附属太和医院,湖北郧阳442000

出　　处：《肿瘤学杂志》2004年第5期318-319,共2页Journal of Chinese Oncology

摘　　要：[目的]探讨以羟基喜树碱为主化疗药物肝动脉栓塞治疗原发性肝癌的临床疗效。[方法]82例原发性肝癌患者,随机分为常规药物组(A组41例)和羟基喜树碱为主化疗药物组(B组41例),两组均给予经皮肝动脉插管化疗栓塞治疗,至少2个疗程,疗效及毒性判定按照WHO标准。[结果]A组CR19.51%,PR21.95%,CR+PR41.46%;B组CR21.95%,PR36.59%,CR+PR58.54%,两组之间差异有显著性。毒副反应两组之间差异无显著性。[结论]以羟基喜树碱为主的化疗药物栓塞治疗原发性肝癌有明显疗效。To evaluate the effect of transcather arterial chemoembolization (TACE) with hydroxycamptothecin for primary liver cancer. Eighty-two cases with primary liver cancer were randomly divided into the conventional drug group (Group A) and the hydroxycamptothecin group (Group B). The two groups were given TACE at least for two cycles, and the efficiency and toxicity were evaluated by WHO's criterion. Group A:CR, 19.51% ; PR, 21.95%; CR+PR, 41.46%. Group B: CR, 21.95%; PR, 36.59% ; CR+PR, 58.54% were found. There was significant difference between two groups and no significant difference in toxicity. [Conclusion] Hydroxycamptothecin-based TACE has a good effect in the treatment for primary liver cancer.

关 键 词：羟基喜树碱 肝肿瘤 栓塞疗法 

分 类 号：R735.7[医药卫生—肿瘤]